Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Neoplasms
75%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
58%
Lima
52%
Leukemia
37%
National Cancer Institute
34%
COVID-19 Pandemic
34%
Human Immunodeficiency Virus Infection
34%
AIDS/HIV
34%
Liver Sarcoma
34%
Lymphadenopathy
34%
Relapsed or Refractory Acute Myeloid Leukemia
34%
Hematological Diseases
34%
Expert Recommendation
34%
HTLV-I Infection
34%
Hypomethylating Agents
34%
Peru
34%
Disease-associated
34%
CD70
34%
Follicular Lymphoma
34%
Rituximab
34%
Myelodysplastic Syndrome
34%
Disease Control
34%
Functional Impairment
34%
CD8 Expression
34%
Randomized Trial
34%
Natural Killer Cells
34%
Involved Field Radiotherapy
34%
Systemic Therapy
34%
Intratumor
34%
Immune Escape
34%
Radiotherapy
34%
Western Population
34%
Genomic Features
34%
Adult T-cell Leukemia
34%
Immunohistochemistry
29%
Tumor
23%
Non-neoplastic
23%
Adult Cells
23%
Cell Lymphoma
23%
Poor Prognosis
23%
Malignancy
22%
Hematopoietic Stem Cells
19%
Cancer Patients
17%
Patient Management
17%
Neoplastic Disease
17%
Global Public Health
17%
Private Clinic
17%
National Hospital
17%
COVID-19
17%
Public Health Emergency
17%
Medicine and Dentistry
Neoplasm
100%
Diseases
55%
Malignant Neoplasm
49%
Infection
46%
Acute Myeloid Leukemia
34%
Human Immunodeficiency Virus Infection
34%
HTLV-1 Infection
34%
Lymphadenopathy
34%
Hypomethylating Agent
34%
Sulfhemoglobinemia
34%
Liver Sarcoma
34%
COVID-19
34%
Follicular Lymphoma
34%
Functional Disease
34%
Rituximab
34%
Drive
34%
Radiation Therapy
34%
Natural Killer Cell
34%
Involved-Field Radiotherapy
34%
Systemic Therapy
34%
Myelodysplastic Syndrome
34%
CD8 Antigen
34%
Immunohistochemistry
30%
Leukemia
26%
Acquired Immune Deficiency Syndrome
23%
Lymphoma Cell
23%
Progression Free Survival
17%
Hazard Ratio
14%
Overall Survival
14%
Cytopenia
13%
Hematopoietic Cell
13%
Rare Tumor
11%
Public Health
11%
T-Helper Cell
11%
T Cell
11%
Population
11%
Spindle Cell
11%
Virogenesis
11%
Bile Duct
11%
Disease Course
11%
Angiofollicular Lymph Node Hyperplasia
11%
Human T-Lymphotropic Virus
11%
Hyaline
11%
Persistent Generalized Lymphadenopathy
11%
Primary Infection
11%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Cancer
11%
Human T-Lymphotropic Virus 1
11%
Immune Response
11%
Targeted Therapy
11%